RMDResMed Inc.
AI adoption · Q1 2026 earnings call
Health CarePiloting
2
extracted from this call
3 / 5
operational, no hard numbers
Not disclosed
no breakout in this call
AI was mentioned briefly and tangentially on this call, primarily in the context of competitive device dynamics and ResMed's own product pipeline. CEO Michael Farrell acknowledged AI as a new technology being adopted in the medical device space, referenced one FDA-cleared AI product (SmartCare), and signaled future AI-enabled therapy development. No financial quantification of AI investments or revenues was provided, and AI was not a central theme of the call.
Adopter
See full leaderboard →27/ 100
51
stage: piloting · max spec: 3
0
no quantified disclosure
35
1 scope
product_embedded
2 AI mentions from this call.
Extracted verbatim from the RMD Q1 2026 earnings call transcript. Speaker, section, and specificity tier surfaced for each mention.
- T3Q&A· CEO· Product-embedded AII wanted to ask about competitive dynamics in the devices segment, mainly in the U.S. Thinking about one of the competitive launches that took place late in 2025—can you speak to the level of noise you have observed in the U.S. around that launch, and whether you have seen any level of market share shift?
“There is new technology called AI. It is more difficult to adopt in the medical space, and we already have one FDA-cleared product in AI that we talked about in SmartCare last quarter. Watch this space from ResMed Inc. We are focused on smaller, quieter, more comfortable, more cloud-connected, and more intelligent therapies. We will bring out more intelligent therapies over time.”
— Michael J. Farrell, RMD earnings callSmartCare - T2Q&A· CEO· Product-embedded AIYou reiterated expectations next year and through 2030 for high single-digit growth and better leverage on the bottom line. From a high level, what are the growth drivers you see? Any new product launches as we go into fiscal 2027?
“I also talked about algorithms and how digital upgrades can also come with hardware upgrades—watch this space.”
— Michael J. Farrell, RMD earnings call
What management wouldn’t quantify.
Analyst questions where management declined to share a specific number. The pattern of refusals is often as informative as the disclosures.
- No quantification of AI-related R&D investment or capex provided.
- No revenue attribution to AI products (including SmartCare) disclosed.
- No detail on the nature, capabilities, or clinical use case of the SmartCare AI product beyond its FDA clearance status.
- No headcount or organizational investment in AI talent disclosed.
- Management referenced future AI-enabled therapy development ('watch this space') without providing timeline, product details, or investment magnitude.
- No analyst directly asked a dedicated AI question; AI commentary was embedded in a competitive dynamics response.
Compare with peers.
Other companies in the same sector and at the same AI adoption stage.
Same GICS sector, all stages
Independent research, direct to your inbox.
Live data tracking and analysis. Deep research that cuts through consensus. Evidence-backed insights.